CLINAPTIS RESEARCH
Browse Learn
LEARN

Understand the science.
Build the investment case.

Plain-English guides to reading clinical evidence, tracking trial disclosures and valuing early-stage biopharma assets. Each guide separates what the evidence shows from what you infer from it.

Guides

New to the field? Start with the four foundation articles. Then read the first two guides in order: what was disclosed, then what the results show. The third turns an evidence-based assumption into a value. BioCo examples are fictional teaching illustrations.

FOUNDATION

What Is Biotechnology?

A plain-English introduction to how biotech works, where it came from and how it differs from pharma.

  • From recombinant insulin to gene and cell therapy
  • Biotech versus pharma, and small molecules versus biologics
  • The main medicine types in 2026
  • Primary sources for further reading
Read the article →
FOUNDATION

How a Drug Gets FDA Approval

From preclinical testing through Phase 1 to 3, FDA review and post-approval studies, and the evidence standard the FDA applies.

  • What each trial phase can and cannot show
  • IND, NDA and BLA in plain English
  • What "substantial evidence of effectiveness" means
  • What happens after approval
Read the article →
FOUNDATION

IND, NDA, BLA & PDUFA Dates

What each FDA application is, who the sponsor is, how long review takes, and what a PDUFA date does and does not promise.

  • IND, NDA, BLA and supplements
  • Standard and priority review timelines
  • Approval versus a Complete Response Letter
  • Clinical, safety and manufacturing problems
Read the article →
FOUNDATION

Drug Patents & Exclusivity

How patents and regulatory exclusivity protect a medicine in the US and Europe, and why neither guarantees a loss-of-exclusivity date.

  • Patents versus exclusivity, and the Orange and Purple Books
  • US exclusivity periods and patent term extension
  • EU 8+2+1 and supplementary protection certificates
  • When a generic or biosimilar can enter
Read the article →
GUIDE 01

Clinical Trial Disclosure Tracking

Turn trial updates into a dated record of what changed, what remains uncertain and which assumptions to review.

  • A source map: registry, protocol, analysis plan, company releases
  • Study dates versus disclosure dates
  • A manual disclosure log
  • From disclosure to model review
Read the guide →
GUIDE 02

Interpreting Clinical Trial Results

Read the endpoint, effect size, uncertainty and safety together before changing an investment assumption.

  • Endpoints, and absolute versus relative effects
  • P-values, confidence intervals and Bayesian intervals
  • Multiplicity, estimands and missing data
  • A checklist for the next readout
Read the guide →

See the Methods Applied

The guides explain the method. The Research section applies it to specific companies and trials, and The Oral GLP-1 Estimand Gap shows how the choice of estimand changes a reported result.

Educational content, not investment advice. Terms